Immunoassay Market Analysis Overview:
In a recent research report by Market Research Community, the Immunoassay market is expected to surpass USD 48.26 Billion by the year 2030, from USD 29.30 Billion in 2021.
Over the projection period, the software and services segment is expected to post a CAGR of 5.0%. This is explained by the rising supply and significant demand for affordable immunoassay services in emerging economies. As an illustration, Sysmex Corporation started offering new coronavirus (SARS-CoV-2) antibody lab assay services in June 2020.
Top Key Players of the Immunoassay Market Analysis:
The report includes a regional analysis and country analysis with the latest trends, along with the major key players including Siemens Healthineers; bioMérieux SA; Abbott Laboratories; Danaher Corporation (Beckman Coulter); Quidel Corporation; Ortho Clinical Diagnostics; Sysmex Corporation; Bio-Rad Laboratories, Inc.; Becton, Dickinson and Company; F. Hoffmann-La Roche AG; Thermo Fisher Scientific, Inc.
Regional Analysis:
North America– (U.S., Canada, Mexico)
Europe- (Germany, France, U.K., Russia, Italy, Spain, BENELUX, Rest of Europe)
Asia Pacific- (China, Japan, India, South Korea, Australia, ASEAN, Rest of Asia Pacific)
Latin America- (Brazil, Argentina, Chile, Rest of Latin America)
Middle East and Africa- (GCC, Turkey, Israel, Rest of MEA)
By End User:
Hospitals
Blood Banks
Clinical Laboratories
Pharmaceutical and Biotech Companies
Academic Research Centers
Others
Blood banks are expected to expand during the forecasted period as more infectious illnesses are detected in these labs during the screening and processing of donated blood. Additionally, ELISA is extensively employed in blood banks since it is easy to execute and requires nothing in the way of specialist tools and equipment.
The Asia Pacific is anticipated to increase at the quickest rate during the projection period. Due to the high prevalence of infectious diseases and the region's big geriatric population. One of the reasons propelling the market in the area is the expanding usage of cutting-edge laboratory techniques and processes for quicker investigation and diagnosis of infectious and chronic illnesses. In addition, the development of molecular kits and the rise in demand for diagnostic reagents are major market drivers.
The Immunoassay market is projected to grow at a significant pace reaching a CAGR of approximately 5.7%, over the forecast period of 2022–2030, despite a considerable fall in product sales during the initial phase of pandemic spread and lockdown restrictions imposed globally.
The study is consolidated into major segments and further into sub-segments, such as by Product (Reagents Kits, Analyzers/Instruments, Others), by Technology (Radioimmunoassay (RIA), Enzyme Immunoassays (EIA)Rapid Test, others) by Application (Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Disease Testing, Autoimmune Diseases, Others) by end use (Hospitals, Blood Banks, Clinical Laboratories, Pharmaceutical, and Biotech Companies, Academic Research Centers, Others) to forecast the market size by value; also includes the analysis of past Immunoassay market dynamics from 2016 – 2021, considering 2021 as the base year.
The research is answerable to the following key questions:
- Where can business owners locate more potential customers during the forecast period, 2022 - 2030?
- How are the major vendors operating in the Immunoassay market planning to reach a potential audience in the emerging economies? Why are sales soaring in certain parts, but dismal in other regions of the world?
- How much are the customers willing to pay for the products and services?
- How much is the dimension of the Immunoassay market catered by the major vendors?
- How often will the customers buy a product or service during the forecast period, 2022 - 2030?
Contact:
